Study of a lab-made cell therapy for lymphoma and leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1/2 trial tests CRC01, a lab-made immune cell therapy, for adults whose lymphoma or B-cell leukemia has come back or did not respond to treatment. If you qualify, the study aims to see how safe CRC01 is and whether it can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 19 years or older and willing to sign consent paperwork
- Have the specific cancer types in this study: large B-cell lymphoma or B-cell acute lymphoblastic leukemia
- For most people: cancer must be relapsed or refractory after at least two chemotherapy treatments (and you must fit the study’s transplant rules)
- Be well enough to qualify for treatment: good oxygen levels, stable heart function (ejection fraction at least 50%), and reasonable kidney/liver numbers
- Have enough blood counts (for example, minimum platelets, neutrophils, and hemoglobin) and no major transfusions in the last 2 weeks
- Be able to provide non-mobilized cells for manufacturing via apheresis (cell collection)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the experimental drug TC011 can help adults with a type of B-cell lymphoma that has come back or stopped responding after at least two rounds of chemotherapy. The study checks for safety and whether the treatment can shrink tumors.
This trial tests a new kind of immune cell therapy for people with certain types of lymphoma that have come back or not responded to previous treatments. The cells are made from your own blood and are designed to find and attack the cancer cells.
This trial tests a new type of immune cell therapy (called AbTCR T-cells) that targets two markers (CD19 and CD22) found on your lymphoma cells. The goal is to see if these modified cells can safely and effectively destroy your cancer when other treatments haven't worked.
This trial tests a new treatment called CLIC-2201 for people with certain types of B cell lymphoma or leukemia that have come back or not responded to previous treatments. It aims to see if this therapy can help control the cancer.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
This study tests a new therapy called RS001 for people with B-cell lymphoma or B-cell leukemia that has not gotten better or has returned after treatment. It targets a marker called CD19 on cancer cells, and the goal is to see if it can help control the cancer.
Hear when a new Relapsed Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.